Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (NCT04224064) | Clinical Trial Compass
RecruitingNot Applicable
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
France158 participantsStarted 2020-08-26
Plain-language summary
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria for LPS patients cohort:
Men/women older than 18 years old,
Surgery for :
* Localized WD-LPS and DD-LPS, and/or
* WD-LPS or DD-LPS local relapse, and/or
* WD-LPS or DD-LPS distant relapse and/or
* Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
Inclusion Criteria for healthy subjects cohort:
Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort
Exclusion Criteria:
Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
Pregnancy and/or feeding
What they're measuring
1
Sensibility and specificity of circulating serine level for LPS diagnosis
Timeframe: At 3 months post surgery
Trial details
NCT IDNCT04224064
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle